CA
NZ
UK
AU
IND
US
● The FDA accepted Biohaven's resubmitted New Drug Application for its therapy, reported as Vyglxia.
● Cytosorbents is a small-cap medical-device company whose shares can swing sharply.
● Estrella is a sub-dollar, clinical-stage micro-cap with thin, sentiment-driven trading.
● FibroBiologics is a low-priced, clinical-stage micro-cap biotech with a small float.
● Third-quarter 2026 results featured a record-revenue streak and a raised 2027 outlook.
● Korro Bio is a small-cap, clinical-stage biotechnology company.
● The gain coincided with strength in select biotechnology names.
● Nanobiotix is a clinical-stage oncology biotech whose shares are sensitive to sentiment.
● Profusa is a low-priced biosensor micro-cap with a small float.
● Pharming is a rare-disease biopharma whose shares moved with sector momentum.
Please wait processing your request...